Results 151 to 160 of about 18,481 (166)

Evaluating an RSV inhibitor

Nature Reviews Microbiology, 2022
exaly  

Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis

Lancet, The, 2020
Mauro Chiarito, Francesco Cannata, Davide Cao   +2 more
exaly  

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

Cancer Cell, 2018
Ewa Gogola, Wouter W Wiegant, Daniel J Vis   +2 more
exaly  

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

Lancet, The, 2010
Uri Lopatin, Patrick F Smith
exaly  

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

Lancet, The, 2011
Klemens Budde, Claudia Sommerer, Petra Reinke   +2 more
exaly  

SWITCH TO AROMATASE INHIBITOR BETTER THAN CONTINUING TAMOXIFEN

Ca-A Cancer Journal for Clinicians, 2005
exaly  

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study

Lancet, The, 1999
Katherine Samaras, Donald J Chisholm
exaly  

Expression of the cyclin-dependent kinase inhibitor p27 in leukemias.

1998
Petrucci MT, GREGORJ, CHIARA, Ariola C, RICCIARDI, Maria Rosaria, Mercurio C, Dominguez JE, Draetta G, TAFURI, Agostino   +7 more
openaire   +1 more source

Hereditary angioedema with normal C1-inhibitor activity in women

Lancet, The, 2000
Konrad Bork
exaly  

Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial

Lancet, The, 2017
Marc A Riedl, Avner Reshef, Sladjana Andrejevic   +2 more
exaly